<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265534</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-014</org_study_id>
    <nct_id>NCT04265534</nct_id>
  </id_info>
  <brief_title>KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC</brief_title>
  <acronym>KEAPSAKE</acronym>
  <official_title>A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor
      telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with
      standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic
      disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung
      cancer (NSCLC). The study primary endpoints are PFS per RECIST v. 1.1 and safety. KEAP1/NRF2
      mutation status (for eligibility) and STK11/LKB1 status (for stratification) will be
      determined by next generation sequencing. A commercial liquid biopsy (circulating tumor DNA)
      NGS test will be provided to study participants free of charge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Duration of investigator-determined PFS per RECIST v1.1 in the intent-to-treat (ITT) population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0</measure>
    <time_frame>Up to 55 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for Patients Treated with Telaglenastat plus Standard-of-Care Pembrolizumab and Chemotherapy versus Placebo plus Standard-of-Care Pembrolizumab and Chemotherapy</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for Patients Treated with Telaglenastat plus Standard-of-Care Pembrolizumab and Chemotherapy versus Placebo plus Standard-of-Care Pembrolizumab and Chemotherapy</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR is defined as the duration of response for patients achieving a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 55 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-squamous Non-small-cell Lung Cancer</condition>
  <condition>Non-Squamous Non-Small Cell Neoplasm of Lung</condition>
  <condition>KEAP1 Gene Mutation</condition>
  <condition>NRF2 Gene Mutation</condition>
  <condition>NFE2L2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaglenastat</intervention_name>
    <description>Oral Glutaminase Inhibitor</description>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>CB-839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin Chemotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Chemotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab Immunotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Oral placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid 400 -1000 μg</intervention_name>
    <description>Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12 1000 μg</intervention_name>
    <description>Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg</intervention_name>
    <description>For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented nonsquamous NSCLC

          -  Stage IV (M1a-c, AJCC 8th Edition) disease not previously treated with systemic
             therapy for metastatic NSCLC

             a. Patients who received adjuvant or neoadjuvant therapy (with or without
             immunotherapy) for localized NSCLC are eligible if all adjuvant/neoadjuvant therapy
             (including immunotherapy) was completed at least 6 months prior to the development of
             metastatic disease.

          -  No known actionable mutation in EGFR, ALK, ROS1, BRAF, NTRK or other known actionable
             mutation for which there is approved therapy.

          -  Measurable disease per RECIST 1.1.

          -  Life expectancy of at least 3 months.

          -  Mutation in KEAP1 or NRF2 documented by NGS from a CAP-accredited and/or
             CLIA-certified laboratory and STK11/LKB1 mutation status is known for the purpose of
             stratification.

          -  Adequate hepatic, renal, cardiac and hematologic function.

          -  Willingness to use adequate contraception as defined in the study protocol

        Exclusion Criteria:

          -  Squamous cell histology and mixed histology tumors with any small-cell component
             (other mixed histology and large cell neuroendocrine histology is allowed).

          -  Known history of malignancy within the past three years except for adequately treated
             basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other
             neoplasm that, in the opinion of the principal investigator and with the agreement of
             the medical monitor, will not interfere with study-specific endpoints.

          -  Had radiation therapy to the lung &gt; 30 Gy within 6 months prior to randomization.

          -  Has active autoimmune disease that has required systemic treatment in past 2 years.

          -  Is currently receiving chronic systemic steroids and/or immunosuppressive drugs.

          -  Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs),
             other than an aspirin dose ≤1.3 g per day, for a 5-day period (8-day period for
             long-acting agents, such as piroxicam).

          -  Unable to swallow oral medications.

          -  Previously had a severe hypersensitivity reaction to treatment with another monoclonal
             antibody (mAb).

          -  Known positivity for Hepatitis B or C.

          -  Is unable or unwilling to take folic acid or vitamin B12 supplementation.

          -  Interstitial lung disease or a history of pneumonitis that required oral or
             intravenous glucocorticoid treatment.

          -  Unable or unwilling to discontinue proton pump inhibitors (PPI) at least 5 days before
             randomization.

          -  Major surgery within 3 weeks of randomization.

          -  Symptomatic ascites or pleural effusion.

          -  Any condition that may preclude adequate absorption of oral study drug.

          -  Patients with active and/or untreated central nervous system metastasis including
             carcinomatous meningitis (leptomeningeal disease) are not eligible. Patients with
             previously treated brain metastases are eligible if they meet the following criteria:

               1. Received definitive treatment with stereotactic radiosurgery (SRS) or surgery to
                  all known central nervous system (CNS) lesions (whole brain radiotherapy is not
                  an eligible modality)

               2. Are at least 7 days post SRS and 4 weeks post-surgical resection of CNS disease,
                  symptomatically stable and off steroids before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Whiting, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Admin</last_name>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Cancer Specialist - South (SCRI)</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Cohen</last_name>
      <email>pcowan@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mabel Martinez</last_name>
      <email>Mabel.martinez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Rama Balaraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - North (SCRI)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinah Welsh-Barnes</last_name>
      <email>dibarnes@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - Panhandle (SCRI)</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Wright</last_name>
      <email>pwright@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Pareshkumar Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Lennox</last_name>
      <email>brianna.lenox@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
      <email>anne.rabenn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Lenox</last_name>
      <email>brianna.lenox@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
      <email>anne.rabenn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Quammen</last_name>
      <email>Heather.Quammen@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health - Centerpoint Medical Center (SCRI)</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stieben</last_name>
      <phone>816-276-4626</phone>
      <email>Susan.Stieben@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Stiwill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health - Menorah Medical Center (SCRI)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stieben</last_name>
      <phone>816-276-4626</phone>
      <email>Susan.Stieben@hcamidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health - Research Medical Center (SCRI)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stieben</last_name>
      <phone>816-276-4625</phone>
      <email>Susan.Stieben@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Stilwill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Cancer Care and Blood Disorders (NJCCBD)</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Johnstone</last_name>
      <phone>973-751-8880</phone>
      <email>trials@njcancercare.com</email>
    </contact>
    <investigator>
      <last_name>James Orsini, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. (400 Patoon Creek Blvd.)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Furqan Ilyas</last_name>
      <email>furqan.ilyas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Makenzi Evangelist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. (43 New Scotland Ave.)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Stanners</last_name>
      <email>christine.stanners@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Makenzi Evangelist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Bingnull</last_name>
      <email>susan.brignull@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Makenzi Evangelist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga (SCRI)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ask Sarah</last_name>
      <phone>844-482-4812</phone>
    </contact>
    <investigator>
      <last_name>Davey Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Moore, CCRP</last_name>
      <phone>615-524-4025</phone>
      <email>Misty.Moore@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>David Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arellano</last_name>
      <email>monica.arellano@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Uyeki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Linley</last_name>
      <email>michelle.linley@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Uyeki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Bailey</last_name>
      <email>terri.bailey2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Uyeki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Joseph</last_name>
      <phone>817-413-1500</phone>
      <email>jennifer.joseph@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Theriault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <email>natasha.holt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Nichols</last_name>
      <email>jessica.nichols@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Florow</last_name>
      <email>christy.florow@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Florow</last_name>
    </contact>
    <contact_backup>
      <last_name>christy.florow@usoncology.com</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jerome Goldschmidt, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Wytheville</city>
        <state>Virginia</state>
        <zip>24382</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Florow</last_name>
      <email>christy.florow@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>KEAP1</keyword>
  <keyword>NRF2</keyword>
  <keyword>NFE2l2</keyword>
  <keyword>LKB1</keyword>
  <keyword>STK11</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>NGS</keyword>
  <keyword>Mutation</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>Telaglenastat</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Front-line</keyword>
  <keyword>First-line</keyword>
  <keyword>Non-squamous</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Alimta</keyword>
  <keyword>Guardant360</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

